Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EchiTAb G
- Development stage
- Unknown
- Lead developer
- MicroPharm
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
EchiTAb G is a monospecific, ovine-derived immunoglobulin G (IgG) antivenom developed to treat systemic envenoming caused by the saw-scaled or carpet viper (*Echis ocellatus*), which is responsible for the majority of snakebite-related deaths in Nigeria and the West African savannah. Developed under a collaboration between the Nigerian Federal Ministry of Health and the EchiTAb Study Group, and manufactured by MicroPharm Ltd in Wales, UK, EchiTAb G consists of caprylic acid-purified whole IgG antibodies raised in sheep against *E. ocellatus* venom. It works by neutralizing the lethal, hemorrhagic, and coagulopathic toxins of the venom, thereby restoring blood coagulability in patients suffering from venom-induced consumption coagulopathy. In a Phase II/III clinical trial in Nigeria, EchiTAb G demonstrated a 75.7% rate of permanent restoration of blood coagulability within 6 hours of administration.
- Brand names
- EchiTAb G
- Other names
- EchiTAbGEchiTAb-GEchis ocellatus antivenom (ovine)
02
Targets
LAAO (L-amino-acid oxidase (Echis ocellatus))SVSP (Snake venom serine protease)svPLA2 (Echis ocellatus venom phospholipase A2)EoCTLP (Echis ocellatus venom C-type lectin-like protein)EoVMPs (Echis ocellatus venom metalloproteinases)
Beyond the preview
Go deeper on EchiTAb G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EchiTAb G.